AI assistant
SynAct Pharma Board/Management Information 2023
3114_rns_2023-02-01_77c7e4b3-4c95-4d03-a8ef-495c2dfebc61.pdf
Board/Management Information
Open in viewerOpens in your device viewer
Patrik Renblad is leaving SynAct Pharma and the search for a new CFO has been initiated
SynAct Pharma AB (publ) ("SynAct") today announced that its Chief Financial Officer, Patrik Renblad has resigned and will move to a new assignment outside of the company. He will leave SynAct by the end of July, 2023, at the latest.
Patrik Renblad joined SynAct in 2021 and has during his tenure been instrumental in preparing the company for and taking the step to a listing of the share at Nasdaq Stockholm's main market, coordinating the acquisition of TXP Pharma and two financing rounds, bringing in 230 mSEK in proceeds.
The process to recruit a new Chief Financial Officer has been initiated.
The information was submitted for publication, through the agency of the contact persons set out below, at 8.00 am CET, February 1, 2023.
For further information about SynAct Pharma AB, please contact: Jeppe Øvlesen CEO, SynAct Pharma AB
Phone: +45 28 44 75 67 Mail: [email protected]
Patrik Renblad
CFO, SynAct Pharma AB Phone: +46 707 47 97 68 Mail: [email protected]
About SynAct Pharma AB
SynAct Pharma AB (publ) (Nasdaq Stockholm: SYNACT) conducts research and development in inflammatory diseases. The company has a platform technology based on a new class of drug candidates aimed at acute deterioration in chronic inflammatory diseases with the primary purpose of stimulating natural healing mechanisms. For more information: www.synactpharma. com.
Attachments
Patrik Renblad is leaving SynAct Pharma and the search for a new CFO has been initiated